Novartis Pharmaceuticals
This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (6 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a decision has already been made to be treated with dabrafenib and trametinib, irrespective of the trial participation.
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Non-investigational
Study Type : | Observational |
Estimated Enrollment : | 40 participants |
Official Title: | Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors |
Actual Study Start Date : | March 3, 2024 |
Estimated Primary Completion Date : | October 26, 2027 |
Estimated Study Completion Date : | February 29, 2028 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 6 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.